Stockpiling anti-viral drugs for a pandemic: The role of Manufacturer Reserve Programs

Joseph E. Harrington; Edbert B. Hsu

doi:10.1016/j.jhealeco.2010.02.004

Stockpiling anti-viral drugs for a pandemic: The role of Manufacturer Reserve Programs

Joseph E. Harrington, Edbert B. Hsu

School of Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.

Original language	English (US)
Pages (from-to)	438-444
Number of pages	7
Journal	Journal of health economics
Volume	29
Issue number	3
DOIs	https://doi.org/10.1016/j.jhealeco.2010.02.004
State	Published - May 2010

Keywords

Pandemic
Pharmaceutical products
Pricing

ASJC Scopus subject areas

Health Policy
Public Health, Environmental and Occupational Health

Access to Document

10.1016/j.jhealeco.2010.02.004

Cite this

@article{d3f7440e845b4328b03581e6f27234cf,

title = "Stockpiling anti-viral drugs for a pandemic: The role of Manufacturer Reserve Programs",

abstract = "To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.",

keywords = "Pandemic, Pharmaceutical products, Pricing",

author = "Harrington, {Joseph E.} and Hsu, {Edbert B.}",

year = "2010",

month = may,

doi = "10.1016/j.jhealeco.2010.02.004",

language = "English (US)",

volume = "29",

pages = "438--444",

journal = "Journal of health economics",

issn = "0167-6296",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Stockpiling anti-viral drugs for a pandemic

T2 - The role of Manufacturer Reserve Programs

AU - Harrington, Joseph E.

AU - Hsu, Edbert B.

PY - 2010/5

Y1 - 2010/5

N2 - To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.

AB - To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.

KW - Pandemic

KW - Pharmaceutical products

KW - Pricing

UR - http://www.scopus.com/inward/record.url?scp=77952541303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952541303&partnerID=8YFLogxK

U2 - 10.1016/j.jhealeco.2010.02.004

DO - 10.1016/j.jhealeco.2010.02.004

M3 - Article

C2 - 20236719

AN - SCOPUS:77952541303

SN - 0167-6296

VL - 29

SP - 438

EP - 444

JO - Journal of health economics

JF - Journal of health economics

IS - 3

ER -

Stockpiling anti-viral drugs for a pandemic: The role of Manufacturer Reserve Programs

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this